To examine the mechanism by which metformin lowers endogenous glucose produ
ction in type 2 diabetic patients, we studied seven type 2 diabetic subject
s, with fasting hyperglycemia (15.5 +/- 1.3 mmol/l), before and after 3 mon
ths of metformin treatment. Seven healthy subjects, matched for sex, age, a
nd BMI,served as control subjects. Rates of net hepatic glycogenolysis, est
imated by C-13 nuclear magnetic resonance spectroscopy, were combined with
estimates of contributions to glucose production of gluconeogenesis and gly
cogenolysis, measured by labeling of blood glucose by H-2 from ingested (H2
O)-H-2. Glucose production was measured using [6,6-H-2(2)]glucose. The rate
of glucose production was twice as high in the diabetic subjects as in con
trol subjects (0.70 +/- 0.05 vs. 0.36 +/- 0.03 mmol m(-2) min(-1), P < 0.00
01). Metformin reduced that rate by 24% (to 0.53 +/- 0.03 mmol.m(-2).min(-1
), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/-
0.9 mmol/l, P = 0.0002). The rate of gluconeogenesis was three times highe
r in the diabetic subjects than in the control subjects (0.59 +/- 0.03 vs.
0.18 +/- 0.03 mmol.m(-2). min(-1)) and metformin reduced that rate by 36% (
to 0.38 +/- 0.03 mmol.m(-2).min(-1), P = 0.01). By the (H2O)-H-2 method, th
ere was a twofold increase in rates of gluconeogenesis in diabetic subjects
(0.42 +/- 0.04 mmol.m(-2).min(-1)), which decreased by 33% after metformin
treatment (0.28 +/- 0.03 mmol.m(-2).min(-1), P = 0.0002). There was no gly
cogen cycling in the control subjects, but in the diabetic subjects, glycog
en cycling contributed to 25% of glucose production and explains the differ
ences between the two methods used, In conclusion, patients with poorly con
trolled type 2 diabetes have increased rates of endogenous glucose producti
on, which can be attributed to increased rates of gluconeogenesis. Metformi
n lowered the rate of glucose production in these patients through a reduct
ion in gluconeogenesis.